EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Naturewise Biotech & Medicals EBITDA Margin % Related Terms
Naturewise Biotech & Medicals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4732 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Naturewise Biotech & Medicals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturewise Biotech & Medicals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Naturewise Biotech & Medicals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturewise Biotech & Medicals (ROCO:4732) has a EBITDA Margin % of -75.74% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Naturewise Biotech & Medicals and its competitors. According to the industry distribution chart, Naturewise Biotech & Medicals ranks #452 out of 943 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Naturewise Biotech & Medicals' EBITDA Margin % too high?
Naturewise Biotech & Medicals' current EBITDA Margin % is -75.74%. Based on the distribution chart, Naturewise Biotech & Medicals ranks #452 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Naturewise Biotech & Medicals has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Naturewise Biotech & Medicals ranks #452 out of 943 companies for EBITDA Margin %. This puts Naturewise Biotech & Medicals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current EBITDA Margin % is -75.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.13, compared to a current price of NT$18.40 — trading 16.9% below its estimated fair value. The current EBITDA Margin % is -75.74%. Naturewise Biotech & Medicals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current EBITDA Margin % is -75.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued.
The current stock price of NT$18.40 is trading 16.9% below its estimated GF Value™ of NT$22.13.
GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.
Key valuation signals for ROCO:4732:
EBITDA Margin %: -75.74%
GF Value™: NT$22.13 vs. price of NT$18.40 (16.9% below fair value)
No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturewise Biotech & Medicals Business Description
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
63GF Score
Get the complete analysis for ROCO:4732
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4732 has been successfully added to your 
